Noho, Inc. is Pink Current on the OTC and Provides Further Updates

Rhea-AI Summary

NOHO, Inc. (OTC PINK: DRNK) has achieved Pink status on the OTC market as all financial statements are filed and approved. The company is engaging a new auditor to initiate the audit process for full SEC reporting. NOHO's website is nearing completion, with the new product After Shot set to launch by August. The company will also market its Delta-8 THC products under the RāD8 brand, following regulatory considerations. A payment processing solution will be introduced to facilitate sales without traditional banking hurdles.

Positive

• Achieved Pink status on the OTC market.
• New product After Shot launching by August.
• Entering Delta-8 THC market with RāD8 brand.

Negative

• None.

News Market Reaction – DRNK

+9.52%

1 alert

+9.52% News Effect

On the day this news was published, DRNK gained 9.52%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Scottsdale, Arizona, July 06, 2021 (GLOBE NEWSWIRE) -- NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the “Company”), announced the following:

The Company has achieved Pink status on the OTC as all current financial statements are filed and approved.

Management would like to thank all shareholders for their patience in this long-awaited process in getting the company current.  The Company is in discussion with a new auditor to begin the audit process and return NOHO to fully reporting status with the SEC.

Revenue and Operations

The NOHO site is in final development and the new After Shot is currently in production.  The Company expects to launch the site by August with product available for sale.  In addition, management has decided to go to market with the sale of its Delta-8 THC products under the RāD8 brand.  While management initially resisted direct to consumer sales to due regulatory concerns, the Company is now comfortable selling consumer products to the vast majority of the country, while avoiding the patchwork of states that do not permit Delta-8 sales and which, fortunately, amount to only a small segment of the overall population.   

As a further benefit, the Company will be introducing its payment processing solution by separate release shortly.  This solution will allow the Company to make sales of Delta-8 without having to seek banking approval and rely on the conventional credit card processing networks that charge high transaction fees.

“NOHO is back to Pink and current in its filings for the first time since 2017.  We are engaged with a new auditor to return the company to fully reporting status with the SEC and we’ll be back in revenue this Summer with new products to follow the initial launch later this month,” said David Mersky, NOHO’s CEO. 

More from NOHO – in addition to the After Shot, we have developed a new line of products, all leveraging Hydro-Nano technology, which will be rolling out soon.  For additional information and product updates, please follow us at www.nohoshot.com and follow NOHO on Twitter at www.twitter.com/nohodrink.

Cautionary Note Regarding Forward-Looking Statements.

This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Noho, Inc. (the “Company”), its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Contact:
IR@TheCampusCo.com

Attachment

• $DRNK NOHO - AFTER SHOT

FAQ

What is the significance of NOHO's Pink status on the OTC market?

NOHO's achievement of Pink status indicates that all current financial statements have been filed and approved, enhancing transparency and compliance.

When will the new product After Shot be available?

The After Shot product is expected to launch by August.

What are NOHO's plans for Delta-8 THC products?

NOHO plans to market its Delta-8 THC products under the RāD8 brand, expanding its product offerings.

Is NOHO planning to return to fully reporting status with the SEC?

Yes, NOHO is in discussion with a new auditor to facilitate its return to fully reporting status with the SEC.